Review article: glucagon‐like peptide 2 – current applications and future directions
- 8 January 2007
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (4) , 365-372
- https://doi.org/10.1111/j.1365-2036.2006.03193.x
Abstract
Glucagon-like peptide 2 (GLP-2) is an important peptide growth factor secreted from the human intestine. The trophic properties of GLP-2 are very specific to the gut where it is pivotal in the regulation of mucosal morphology, function and integrity. This review details the current understanding of the molecular biology of GLP-2, its mechanisms of action and physiological properties. A major focus is the discussion of recent clinical data evaluating the use of GLP-2 as a therapeutic agent. Relevant articles were identified using Medline searches and from the reference lists of key papers. In the treatment of short bowel syndrome, GLP-2 has been shown to be highly effective in improving fluid absorption. In Crohn's disease, GLP-2 is superior to placebo in the induction of remission. Early data also suggest that the effects of GLP-2 on bone metabolism can provide a new treatment approach for patients with osteoporosis. In the future, the positive effects of GLP-2 on intestinal barrier function, splanchnic perfusion and mucosal healing could be utilized to expand its therapeutic application to other causes of intestinal injury. However, important safety aspects need to be considered when using this potent growth-promoting agent for a long term.Keywords
This publication has 62 references indexed in Scilit:
- Stress Impairs Murine Intestinal Barrier Function: Improvement by Glucagon-Like Peptide-2The Journal of Pharmacology and Experimental Therapeutics, 2005
- Intestinal Growth in Parenterally‐Fed Rats Induced by the Combined Effects of Glucagon‐like Peptide 2 and Epidermal Growth FactorJournal of Parenteral and Enteral Nutrition, 2005
- Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1Biochemical and Biophysical Research Communications, 2005
- Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndromeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
- Glucagon-like peptide 2: an updateCurrent Opinion in Endocrinology, Diabetes and Obesity, 2005
- Glucagon‐like peptide‐2 inhibits antral emptying in man, but is not as potent as glucagon‐like peptide‐1Scandinavian Journal of Gastroenterology, 2004
- Role of Gastrointestinal Hormones in Postprandial Reduction of Bone ResorptionJournal of Bone and Mineral Research, 2003
- Glucagon-Like Peptide-2 and Common Therapeutics in a Murine Model of Ulcerative ColitisThe Journal of Pharmacology and Experimental Therapeutics, 2003
- GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1 1This work is a publication of the USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas.Gastroenterology, 2003
- In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in HumansJournal of Clinical Endocrinology & Metabolism, 2000